Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Abiraterone + Goserelin + Prednisone + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abiraterone||Zytiga||CB7630||Hormone - Anti-androgens 47||Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).|
|Goserelin||Zoladex||Goserelin acetate||Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females, and is FDA approved for use in prostate carcinoma (FDA.gov).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 29||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations, and in combination with Xtandi (enzalutamide) in patients with homologous recombination repair gene (ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C)-mutated metastatic castration-resistant prostate cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04734730||Phase II||Abiraterone + Bicalutamide + Leuprolide + Prednisone + Talazoparib Abiraterone + Goserelin + Prednisone + Talazoparib Abiraterone + Degarelix + Prednisone + Talazoparib||Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer||Recruiting||USA||0|